Follow Us:
4th Symposium on Current Strategies in the Treatment of Multiple Myeloma, Lymphoma and Leukemia
This webcast is jointly provided by A. Webb Roberts Center for CME of Baylor Health Care System and CancerNet.
For more information visit: www.cancernetus.net
 |
 |
Grantors:
Pfizer
Onyx Pharmaceuticals, Inc., a subsidiary of Amgen, Inc.
Bristol-Myers Squibb
Millennium Pharmaceuticals, Inc.
Novartis Pharmaceuticals, Inc.
Seattle Genetics, Inc.
Release date: May 25, 2015
Valid through: May 25, 2016
Specialty: Hematology/Oncology
Media: Internet
Target Audience
This symposium is directed primarily to hematologists/oncologists, radiation oncologists, researchers, pharmacists, registered nurses, physician assistants, nurse practitioners and fellows in training interested in new development in hematological malignancies. No specific skill or knowledge other than a basic training in hematology/oncology is required for successful participation in this activity.
Statement of Need / Program Overview
This symposium is intended to improve care of patients with hematological malignancies by accelerating adoption of new guidelines and evidence-based practice change. In addition to chemotherapy and targeted therapy of hematological malignancies, this symposium will focus on individualized treatment options. In-depth discussion of novel agents at various stages of clinical development will be given significant focus. This enduring online activity is designed to provide clinical decision-making strategies for integration of novel therapeutic options.
This program consists of 6 continuing education activites.
Click the links below to review the activity launch pages containing full disclosure information.
Module 1 — 1.0 AMA PRA Category 1 Credits™
Faculty
Gareth Morgan, MD, PhD, Professor of Medicine, Director of the Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR
Michael Wang, MD, Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX
Module 2 — 1.0 AMA PRA Category 1 Credits™
Faculty
Michael Wang, MD, Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX
Elisabet E. Manasanch, MD, Assistant Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX
Module 3 — 1.25 AMA PRA Category 1 Credits™
Faculty
Fredrick B. Hagemeister, MD, Professor of Hematology/Oncology, Department of Lymphoma/ Myeloma, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX
Nathan H. Fowler, MD, Associate Professor, Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
Module 4 — 1.5 AMA PRA Category 1 Credits™
Faculty
Fredrick B. Hagemeister, MD, Professor of Hematology/Oncology, Department of Lymphoma/ Myeloma, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX
Michelle A. Fanale, MD,Assistant Professor, Department of Lymphoma/ Myeloma, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX
Module 5 — 1.5 AMA PRA Category 1 Credits™
Faculty
Elias Jabbour, MD, Associate Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Guillermo Garcia-Manero, MD, Professor of Medicine, Chief, Section of MDS, Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX
Module 6 — 0.5 AMA PRA Category 1 Credits™
Faculty
David Hui, MD, Assistant Professor, Department of Palliative Care and Rehabilitation Medicine, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX